Form 4 for BIIB Biogen
Accepted 2022-12-06 00:00:00 ET · period of report 2022-12-02 · accession 0001127602-22-026992 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-06 | 2022-12-02 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $298.90 | -39 | 2,768 | -1% | -$11.7K |
| D | 2022-12-06 | 2022-12-02 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +131 | 2,807 | +5% | $0 |
| D | 2022-12-06 | 2022-12-02 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -131 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-02 | F | D | 39 | $298.90 | 2,768.29 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-02 | M | A | 131 | $0.00 | 2,807.29 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2022-12-02 | M | D | 131 | $0.00 | 0 | D | $0.00 · — to 2022-12-02 | 131 Common Stock | (F1) This award was granted to the reporting person on December 2, 2019 and vested in three equal installments on each anniversary of the grant date. |